News

The latest from Velocity Clinical Research

Drs. Essink and Overcash Author Article Featured in Nature Communications for Moderna COVE Study

August 30, 2024

Brandon Essink, MD, CPI, and J. Scott Overcash, MD, were authors of a recent Nature Communications article, “Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.” From the article: “Boosting elicited greater immune responses against SARSCoV-2 than primary … Read more

VISION Reaches $2 Million in Patient Stipends Paid Globally

August 22, 2024

Since launching in-app stipend payments, Velocity has paid more than $2 million to patients globally through VISION. The mobile app has also contributed to more than 2,500 patient randomizations, empowering users to get matched with clinical trials, self-screen, and self-schedule visits, all at times … Read more

Kris Kowdley, MD, Supported Research Leading to Accelerated FDA Approval of Gilead’s Livdelzi® for Primary Biliary Cholangitis

August 15, 2024

Another milestone for patients with primary biliary cholangitis (PBC) — Gilead’s Livdelzi® (seladelpar) has received accelerated FDA approval as a second-line treatment for PBC. Kris Kowdley, MD, AGAF, FAASLD, FACP, FAC, was an author of the Phase 3 trial results published in the New … Read more

An interview with Dr. Robert Cupelo on Alzheimer’s Treatment and the Legacy of Lecanemab

August 8, 2024

It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. This marked a turning point in the disease’s treatment, a drug that interrupted progression for the first time rather than simply … Read more

Velocity appoints ICON exec Rachael Buck Ph.D. as Head of U.K.

August 7, 2024

Velocity Clinical Research, the leading multi-specialty clinical sites business, today announces the appointment of Rachael Buck Ph.D. as Country Head in the U.K. Rachael will lead the five sites Velocity currently owns and operates in the U.K. and will work with the rest of … Read more

Velocity Sites and Investigators Supported Research for Nine Products That Have Received FDA Approval in 2024

July 30, 2024

Velocity sites and investigators have supported research for nine products that have received U.S. FDA approval in 2024. These include, but are not limited to: Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), the first FDA-approved #MASH drug. Moderna’s mRESVIA, an mRNA RSV vaccine for adults 60 and … Read more

Mike Zaranek Joins Velocity as CFO

July 16, 2024

Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, today announces it has appointed Mike Zaranek as Chief Financial Officer (CFO). Reporting to Velocity President and CEO Paul Evans with immediate effect, Zaranek will direct the company’s financial goals and accounting, and advise … Read more

VISION Engage Reaches $1 Million in Patient Study Stipends Paid

July 15, 2024

Velocity has now paid more than $1.1 million in patient study stipends through our VISION Engage app. Here’s why this matters: Patients get: Prompt, secure in-app payments Direct bank transfers or virtual debit card options Enhanced visibility and flexibility Sites get: Seamless integration with … Read more

A Lean-Value Approach to Technical Product Management

July 9, 2024

Raghu Punnamraju, Chief Technology Officer at Velocity, was recently interviewed by CIO News about applying a lean-value approach to our technical product management, engineering, and architectural strategies. Through the development of our VISION platform, and new frameworks that leverage LLMs, this article details how … Read more

The Importance of Diversity in Clinical Trials with Dr. Jerome Adams

July 8, 2024

The Velocity team had the honor of hosting former U.S. Surgeon General and Chairman of the Board of TOTAL Diversity Clinical Trial Management, Jerome Adams, MD, MPH. He joined an internal call to discuss the importance of diversity in clinical research, highlighting the need … Read more

Velocity Announces New Site in St. Louis, Missouri

July 2, 2024

Velocity has announced a new site in St. Louis, its first in Missouri. The site will be co-located with West County Rheumatology, one of the largest and most active infusion centers in the Midwest, and a region-leading clinic for patients with rheumatoid arthritis, psoriatic … Read more

Closing the gap: Breaking weight-based stigma in clinical trials

June 27, 2024

The narrative that’s been peddled for the past three decades has seen obesity become mired in controversy, leading many – even healthcare professionals – to view it as a lifestyle choice rather than a disease. Nearly 40% of the global population has a body … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.